The Long Game in Endometrial Cancer:
Interpreting PFS, OS, and the Power of Biomarkers Industry Supported Symposium
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers Industry Supported Symposium being held in-person at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa on Wednesday, November 5, 2025 from 13:05 – 14:35 GMT+2.
This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning.
Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making. This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear.
This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.
The GOG Foundation, Inc. is grateful for our commercial supporter for their unrestricted educational grant associated with this Symposium: GSK
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.
Learning Objectives
Upon completion of the activities in this series, learners will be able to:
- Evaluate and compare recent clinical trial designs and key efficacy outcomes in endometrial cancer, with a focus on how differences in methodology and population selection—particularly in dMMR cohorts—impact therapeutic positioning in a dynamic and evolving treatment landscape.
- Interpret findings from recent Phase III Trials and implications specific to subgroup analyses of progression-free and overall survival (PFS/OS) in biologically defined populations, including dMMR, MMRp, and explorative subgroups i.e., P53 mutation status, HRD, and IO-sensitive subgroups, to guide personalized treatment strategies.
- Assess the implications of unplanned subgroup analyses and regulatory approvals, including FDA decisions, on the application of clinical trial data to real-world treatment decisions for patients with dMMR and other molecular subtypes of endometrial cancer (MMR, P53WT, HRD) focusing on how these factors influence treatment options and patient outcomes.
- Understanding current gaps and unmet needs in the management of endometrial cancer, identifying the differential needs in dMMR, MMRp populations, and explore future outlook in treatments, including ongoing and upcoming clinical trials, novel therapeutic targets and how emerging therapies are addressing limitations in existing treatment paradigms. Strategies to address resistance, improve outcomes and close gaps in care will also be discussed.
- Apply clinical trial data and biomarker insights to real-world patient cases, using a case-based approach to evaluate treatment strategies for dMMR and other biomarker-defined subgroups in both frontline and recurrent settings.
Agenda
The Long Game in Endometrial Cancer: Interpreting PFS, OS, and the Power of Biomarkers, an Industry Supported Symposium at the IGCS 2025 Annual Global Meeting
This session is not included in the main event CME/CPD credit.
In Person on Wednesday, November 5, 2025 from 13:05 – 14:35 GMT+2 in Cape Town, South Africa
Ramez N. Eskander, MD, University of California San Diego Health, Moores Cancer Center, San Diego, California, USA
Robert Coleman, MD, Texas Oncology, Austin, Texas, USA
Ramez N. Eskander, MD, University of California San Diego Health, Moores Cancer Center, San Diego, California, USA
Bhavana Pothuri, MD, NYU Langone, Perlmutter Cancer Center, New York, New York, USA
Charlie Gourley, MD, PhD, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK
All Faculty